Subtype
Gastric Carcinoma
CI-CAN-00002732Explore in graph →
183 active trials3 approved drugs37 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002732Explore in graph →
Clinical trials
587 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (65)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer(DisTinGuish) | terminated | Phase 2 | 247 | Leap Therapeutics, Inc.INDUSTRY | 3 | Oct 9, 2025 | clinicaltrials |
| NCT07212933 | The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial(RAK in GC) | recruiting | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 |
| Oct 8, 2025 |
| clinicaltrials |
| NCT07213115 | Epidemiology and Treatment of Gastric Cancer | completed | — | 8,582 | Medizinische Hochschule Brandenburg Theodor FontaneOTHER | 0 | Oct 8, 2025 | clinicaltrials |
| NCT02738294 | Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB | completed | N/A | 211 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02968069 | A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions | not yet recruiting | N/A | 300 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06902337 | Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany(MaGen) | active not recruiting | — | 75,000 | Medizinische Hochschule Brandenburg Theodor FontaneOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04665687 | Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients | recruiting | — | 1,730 | Samsung Medical CenterOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06728891 | Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy(zypg001) | recruiting | — | 100 | Jichao QinOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06736847 | Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer(zydgc001) | recruiting | — | 200 | Jichao QinOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
| NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection(BRIGHT) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT02013154 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab(P102) | completed | Phase 1 | 151 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT04681248 | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | no longer available | — | — | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06732856 | A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer(NEO-CLAUD) | recruiting | Phase 1 / Phase 2 | 57 | Asan Medical CenterOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT07047937 | Explainable Machine Learning for Predicting Early Gastric Cancer | enrolling by invitation | — | 10 | Wenzhou Central HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06943768 | Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test | not yet recruiting | — | 9,654 | Fudan UniversityOTHER | 0 | Jun 24, 2025 | clinicaltrials |
| NCT07034742 | Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer | recruiting | Early Phase 1 | 136 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06728657 | Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma(TORCH-G) | suspended | Phase 2 | 68 | Fudan UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07018063 | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer(YOUNG-NEOS) | not yet recruiting | Phase 2 | 35 | zhoujingOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial(PLATFORM) | active not recruiting | Phase 2 | 494 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07014254 | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | not yet recruiting | N/A | 20 | Xijing HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | terminated | Phase 1 / Phase 2 | 28 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Jun 8, 2025 | clinicaltrials |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | active not recruiting | Phase 1 / Phase 2 | 192 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors(RIOT3) | recruiting | Phase 1 | 18 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT04850729 | Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | recruiting | — | 169 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06997302 | A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies | active not recruiting | N/A | 150 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06980389 | Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) | not yet recruiting | Phase 2 | 176 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04161781 | A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | — | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05311176 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)(nextHERIZON) | terminated | Phase 2 | 7 | Imugene LimitedINDUSTRY | 2 | May 11, 2025 | clinicaltrials |
| NCT06962293 | Magnetic Guided Counetrtraction During Endoscopic Submucosal Dissection | recruiting | N/A | 20 | Chinese University of Hong KongOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06742411 | XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC | recruiting | Phase 1 / Phase 2 | 57 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT04032119 | RCT of Gastric ESD With or Without Epineprhine Added Solution | completed | Phase 3 | 800 | Chinese University of Hong KongOTHER | 4 | May 4, 2025 | clinicaltrials |
| NCT06942767 | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | not yet recruiting | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 3 | 616 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06938139 | Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy | active not recruiting | — | 90,000 | Fujian Medical UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03064490 | Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)(PROCEED) | completed | Phase 2 | 35 | Duke UniversityOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04602026 | The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer(RIOT) | completed | N/A | 66 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03123042 | Feasibility Study of Sentinel Navigation Surgery After Non-curative Endoscopic Resection(SENORITA2) | completed | N/A | 243 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT03429816 | OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma(OPPOSITE) | completed | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 9, 2025source: clinicaltrials